Saltar al contenido
También en Efectos adversosAntidepresivos y suicidalidadLa advertencia enmarcada en menores de 25 años, con sus NNT y NNH, y lo que los ensayos no alcanzan a decir.

§De dónde sale cada cifra

Toda cifra de esta página lleva su fuente, y cada fuente se verificó en PubMed antes de citarla. Lo que no pudimos verificar se dice que falta: en esta página hay 36 huecos declarados a propósito.

Un aviso sobre el conjunto: la mayoría de estas cifras vienen de metaanálisis cuyos autores califican su propia certeza de baja o muy baja. Eso no las invalida, porque son lo mejor que hay, pero sí obliga a usarlas como orientación de magnitud, no como constantes.

  1. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-53. PMID 24677189. https://doi.org/10.1007/s40263-014-0157-3
  2. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-51. PMID 31303314. https://doi.org/10.1016/S0140-6736(19)31135-3
  3. Schneider-Thoma J, Zhu Y, Qin M, et al. Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. Lancet. 2026;407(10531):876-91. PMID 41763745. https://doi.org/10.1016/S0140-6736(25)02365-7
  4. Balijepalli C, Druyts E, Zoratti MJ, et al. Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a network meta-analysis. Schizophr Res Treatment. 2018;2018:1543034. PMID 29805808. https://doi.org/10.1155/2018/1543034
  5. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314. PMID 15456328. https://doi.org/10.2165/00003495-200464200-00003
  6. Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis. Curr Osteoporos Rep. 2016;14(6):249-59. PMID 27696144. https://doi.org/10.1007/s11914-016-0325-0
  7. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010;71(3):338-47. PMID 20331935. 83 varones de 7 a 17 anos, tratados una media de 2,9 anos. https://doi.org/10.4088/JCP.08m04595gre
  8. Papazoglou AS, Leite AR, Moysidis DV, et al. Serum prolactin levels and mortality in adults without prolactinoma: a meta-analysis. J Clin Endocrinol Metab. 2024;109(8):e1652-64. PMID 38366650. 28 estudios revisados, 14 agrupables, 23.596 personas. Poblacion general, no psiquiatrica. https://doi.org/10.1210/clinem/dgae087
  9. Gopal S, Lane R, Nuamah I, et al. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone extended-release for 2 years: a post hoc analysis of an open-label multicenter study. CNS Drugs. 2017;31(9):797-808. PMID 28660406. 400 adolescentes de 12 a 17 anos; 184 completaron los dos anos. Analisis post hoc, abierto y sin placebo, financiado por el fabricante. https://doi.org/10.1007/s40263-017-0437-9
  10. Giri D, Sanam T, Oppenheim A, Senniappan S, Das U. Management of risperidone induced hyperprolactinemia in an adolescent with severe autism. Horm Res Paediatr. 2015;84(Suppl 1):P3-1114. 54.º congreso de la ESPE, Barcelona. Un caso. Resumen de congreso: no esta indexado en PubMed y no tiene DOI, y por eso se cita solo para lo que un caso puede sostener. https://abstracts.eurospe.org/hrp/0084/hrp0084p3-1114
  11. Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One. 2013;8(8):e70179. PMID 23936389. https://doi.org/10.1371/journal.pone.0070179
  12. Zhang L, Qi H, Xie YY, et al. Efficacy and safety of adjunctive aripiprazole, metformin, and paeoniae-glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trials. Front Psychiatry. 2021;12:728204. PMID 34658963. https://doi.org/10.3389/fpsyt.2021.728204
  13. Labad J, Montalvo I, González-Rodríguez A, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res. 2020;222:88-96. PMID 32507371. https://doi.org/10.1016/j.schres.2020.04.031
  14. Meng M, Li W, Zhang S, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry. 2015;27(1):4-17. PMID 25852251. https://doi.org/10.11919/j.issn.1002-0829.215014
  15. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry. 2005;66(1):100-6. PMID 15669895. https://doi.org/10.4088/jcp.v66n0114
  16. Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329-34. PMID 32172535. https://doi.org/10.5694/mja2.50522
  17. de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. The facts about sexual (dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41(3):674-86. PMID 25721311. https://doi.org/10.1093/schbul/sbv001
  18. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62(Suppl 3):10-21. PMID 11229449 (sin DOI en el registro de PubMed).
  19. Winter J, Curtis K, Hu B, Clayton AH. Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management. Expert Opin Drug Saf. 2022;21(7):913-30. PMID 35255754. https://doi.org/10.1080/14740338.2022.2049753
  20. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-66. PMID 19440080. https://doi.org/10.1097/JCP.0b013e3181a5233f
  21. Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc. 2016;91(9):1280-6. PMID 27594188. Revision narrativa, no sistematica. Se cita para su propio marco clinico; cada ensayo que menciona se cita aparte y contra su original. https://doi.org/10.1016/j.mayocp.2016.04.033
  22. Lorenz TA, Meston CM. Acute exercise improves physical sexual arousal in women taking antidepressants. Ann Behav Med. 2012;43(3):352-61. PMID 22403029. Laboratorio, 47 mujeres, tres sesiones contrabalanceadas. https://doi.org/10.1007/s12160-011-9338-1
  23. Rosenberg KP, Bleiberg KL, Koscis J, Gross C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther. 2003;29(4):289-96. PMID 14504017. Encuesta, 51 ambulatorios con enfermedad mental grave. https://doi.org/10.1080/00926230390195524
  24. Bonierbale M, Lançon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin. 2003;19(2):114-24. PMID 12740155. Transversal, 4.557 pacientes con episodio depresivo mayor, tratados y no tratados. https://doi.org/10.1185/030079902125001461
  25. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-8. PMID 18978095. 31.581 mujeres de poblacion general, no psiquiatrica. https://doi.org/10.1097/AOG.0b013e3181898cdb
  26. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40. PMID 10693114. https://doi.org/10.1080/009262300278623
  27. Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med. 2014;126(2):91-9. PMID 24685972. Revision narrativa; origen de la tabla de frecuencia relativa por dominio. https://doi.org/10.3810/pgm.2014.03.2744
  28. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;2013(5):CD003382. PMID 23728643. 23 ECA, 1.886 personas. https://doi.org/10.1002/14651858.CD003382.pub3
  29. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289(1):56-64. PMID 12503977. ECA doble ciego, 90 hombres. https://doi.org/10.1001/jama.289.1.56
  30. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, DeBattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300(4):395-404. PMID 18647982. ECA doble ciego, 98 mujeres. https://doi.org/10.1001/jama.300.4.395
  31. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004;65(1):62-7. PMID 14744170. ECA doble ciego, n = 42. https://doi.org/10.4088/jcp.v65n0110
  32. de Aquino ACQ, Sarmento ACA, Teixeira RLA, et al. Pharmacological treatment of antidepressant-induced sexual dysfunction in women: a systematic review and meta-analysis of randomized clinical trials. Clinics (Sao Paulo). 2025;80:100602. PMID 39985829. 11 ECA y 859 mujeres; solo dos estudios agrupables; certeza GRADE baja. https://doi.org/10.1016/j.clinsp.2025.100602
  33. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036-48. PMID 26331383. ECA cabeza a cabeza, n = 447. https://doi.org/10.1111/jsm.12980
  34. Fooladi E, Bell RJ, Jane F, Robinson PJ, Kulkarni J, Davis SR. Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial. J Sex Med. 2014;11(3):831-9. PMID 24433574. ECA, 44 mujeres de 35 a 55 anos; el desenlace primario fue negativo. https://doi.org/10.1111/jsm.12426
  35. Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-6. PMID 31498871. Consenso de once sociedades; las recomendaciones de practica son opinion de expertos. https://doi.org/10.1210/jc.2019-01603
  36. Droguerias Colsubsidio. Androgel 1 % gel topico, testosterona 10 mg/g; registro INVIMA 2019M-0002965-R2; venta bajo formula medica. Consultado el 5 de octubre de 2026. Fuente comercial, no regulatoria: sirve para saber que se vende, no para la indicacion. https://www.drogueriascolsubsidio.com/androgel-1-gel-topico-3700039500386/p
  37. Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. J Nerv Ment Dis. 2013;201(4):266-73. PMID 23538970. Analisis secundario de un ECA; la funcion sexual se midio con items sueltos de escalas de depresion. https://doi.org/10.1097/NMD.0b013e318288d298
  38. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152(10):1514-6. PMID 7573593. Serie abierta, 30 pacientes, sin grupo control. https://doi.org/10.1176/ajp.152.10.1514
  39. Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19(3):268-71. PMID 10350034. El desenlace sexual no era el primario del ensayo. https://doi.org/10.1097/00004714-199906000-00012
  40. Michelson D, Bancroft J, Targum S, Kim Y, Tepner R. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry. 2000;157(2):239-43. PMID 10671393. Negativo para buspirona y amantadina, 57 mujeres. https://doi.org/10.1176/appi.ajp.157.2.239
  41. Lorenz TA, Meston CM. Exercise improves sexual function in women taking antidepressants: results from a randomized crossover trial. Depress Anxiety. 2014;31(3):188-95. PMID 24754044. ECA cruzado, 52 mujeres. https://doi.org/10.1002/da.22208
  42. King VL, Horowitz IR. Vaginal anesthesia associated with fluoxetine use. Am J Psychiatry. 1993;150(6):984-5. PMID 8494083. Carta, reporte de caso. https://doi.org/10.1176/ajp.150.6.984b
  43. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54-60. PMID 23280545. ECA, 38 mujeres, 4 semanas. https://doi.org/10.1002/hup.2282
  44. Dording CM, Schettler PJ, Dalton ED, et al. A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women. Evid Based Complement Alternat Med. 2015;2015:949036. PMID 25954318. ECA, 45 mujeres aleatorizadas, 42 analizadas. https://doi.org/10.1155/2015/949036
  45. Farnia V, Hojatitabar S, Shakeri J, et al. Adjuvant Rosa damascena has a small effect on SSRI-induced sexual dysfunction in female patients suffering from MDD. Pharmacopsychiatry. 2015;48(4-5):156-63. PMID 26098128. ECA, 50 mujeres, 8 semanas. https://doi.org/10.1055/s-0035-1554712
  46. Khamba B, Aucoin M, Lytle M, et al. Efficacy of acupuncture treatment of sexual dysfunction secondary to antidepressants. J Altern Complement Med. 2013;19(11):862-9. PMID 23790229. Sin grupo control. https://doi.org/10.1089/acm.2012.0751
  47. Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol. 2002;17(6):279-84. PMID 12404672. Negativo, n = 37. https://doi.org/10.1002/hup.409
  48. Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol. 2004;19(8):545-8. PMID 15378664. Negativo, n = 24. https://doi.org/10.1002/hup.627
  49. Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65-76. PMID 34719438. Criterios de consenso de panel, no de cohorte. https://doi.org/10.3233/JRS-210023
  50. Ben-Sheetrit J, Hermon Y, Birkenfeld S, Gutman Y, Csoka AB, Toren P. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry. 2023;22(1):15. PMID 37085865. Cohorte retrospectiva de 19 años, 12.302 hombres. https://doi.org/10.1186/s12991-023-00447-0
  51. Ben-Sheetrit J, Aizenberg D, Csoka AB, Weizman A, Hermesh H. Post-SSRI sexual dysfunction: clinical characterization and preliminary assessment of contributory factors and dose-response relationship. J Clin Psychopharmacol. 2015;35(3):273-8. PMID 25815755. Encuesta en un foro de PSSD, 532 respuestas; no permite estimar incidencia. https://doi.org/10.1097/JCP.0000000000000300
  52. Studt A, Gannon M, Orzel J, Vaughan A, Pearlman AM. Characterizing post-SSRI sexual dysfunction and its impact on quality of life through an international online survey. Int J Risk Saf Med. 2021;32(4):321-9. PMID 34366299. Encuesta en línea autoseleccionada, n = 239. https://doi.org/10.3233/JRS-210039
  53. Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and SSRI or SNRI antidepressants with serotonin syndrome. JAMA Neurol. 2018;75(5):566-72. PMID 29482205. 19.017 pacientes coprescritos, 30.928 personas-año. https://doi.org/10.1001/jamaneurol.2017.5144
  54. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361-5. PMID 17874986. https://doi.org/10.5694/j.1326-5377.2007.tb01282.x
  55. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-42. PMID 12925718. 2.222 ingresos por sobredosis. https://doi.org/10.1093/qjmed/hcg109
  56. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-13. PMID 2035713. Revision de 12 informes y 38 casos, no una cohorte. https://doi.org/10.1176/ajp.148.6.705
  57. Chiew AL, Isbister GK. Serotonin toxicity: pathophysiology, incidence, clinical assessment and management. Br J Clin Pharmacol. 2024;91(3):654-61. PMID 38926083. https://doi.org/10.1111/bcp.16152
  58. Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. JAMA Netw Open. 2022;5(12):e2247426. PMID 36534400. 1.134 ambulatorios, cohorte poblacional con emparejamiento por puntaje de propension. https://doi.org/10.1001/jamanetworkopen.2022.47426
  59. King E, Rotella JA. Efficacy of cyproheptadine in the management of serotonin toxicity following deliberate self-poisoning: a systematic review. Emerg Med Australas. 2025;37(1):e14554. PMID 39791184. Certeza muy baja: la eficacia no quedo establecida. https://doi.org/10.1111/1742-6723.14554
  60. Lao KSJ, Zhao J, Blais JE, et al. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs. 2020;34(11):1165-75. PMID 33010024. https://doi.org/10.1007/s40263-020-00767-9
  61. Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327-69. PMID 37039129. https://doi.org/10.1177/02698811231158232
  62. Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222-8. PMID 21733489. https://doi.org/10.4088/JCP.10m06438
  63. Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;20(1):17r02185. PMID 29325237. https://doi.org/10.4088/PCC.17r02185
  64. Guinart D, Misawa F, Rubio JM, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021;144(4):329-41. PMID 34358327. https://doi.org/10.1111/acps.13359
  65. Kuhlwilm L, Schönfeldt-Lecuona C, Gahr M, Connemann BJ, Keller F, Sartorius A. The neuroleptic malignant syndrome: a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr Scand. 2020;142(3):233-41. PMID 32659853. https://doi.org/10.1111/acps.13215
  66. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-78. PMID 28146614. https://doi.org/10.4088/JCP.16r10832
  67. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330-40. PMID 30192088. https://doi.org/10.1002/wps.20579
  68. Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess. 2017;21(43):1-218. PMID 28812541. https://doi.org/10.3310/hta21430
  69. Kalniunas A, Chakrabarti I, Mandalia R, Munjiza J, Pappa S. The relationship between antipsychotic-induced akathisia and suicidal behaviour: a systematic review. Neuropsychiatr Dis Treat. 2021;17:3489-97. PMID 34887662. https://doi.org/10.2147/NDT.S337785
  70. Gerolymos C, Barazer R, Yon DK, Loundou A, Boyer L, Fond G. Drug efficacy in the treatment of antipsychotic-induced akathisia: a systematic review and network meta-analysis. JAMA Netw Open. 2024;7(3):e241527. PMID 38451521. https://doi.org/10.1001/jamanetworkopen.2024.1527
  71. Lima AR, Bacalcthuk J, Barnes TRE, Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004;(4):CD001946. PMID 15495022. https://doi.org/10.1002/14651858.CD001946.pub2
  72. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2002;(1):CD001950. PMID 11869614. Un solo ensayo utilizable, n = 27. https://doi.org/10.1002/14651858.CD001950
  73. Mancini V, Latreche C, Fanshawe JB, et al. Anticholinergic burden and cognitive function in psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2025;182(4):349-59. PMID 40007252. https://doi.org/10.1176/appi.ajp.20240260
  74. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-84. PMID 28320223. https://doi.org/10.1176/appi.ajp.2017.16091037
  75. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. PMID 28668671. https://doi.org/10.1016/S2215-0366(17)30236-5
  76. Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs. 2017;31(12):1083-91. PMID 29230675. https://doi.org/10.1007/s40263-017-0481-5
  77. Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs. 2019;33(1):81-91. PMID 30456745. https://doi.org/10.1007/s40263-018-0587-4
  78. Braund TA, Tillman G, Palmer DM, Gordon E, Rush AJ, Harris AWF. Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. Transl Psychiatry. 2021;11(1):417. PMID 34349116. 1008 adultos, aleatorizado y abierto, sin placebo. Financiado por Brain Resource. Los eventos uno por uno están en su tabla suplementaria 8; aquí se sumaron las variantes de escritura de cada término. https://doi.org/10.1038/s41398-021-01533-1
  79. Cohen D, Bogers JPAM, van Dijk D, Bakker B, Schulte PFJ. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307-12. PMID 23140648. https://doi.org/10.4088/JCP.11r06977
  80. Shirazi A, Stubbs B, Gomez L, et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016;17(6):863. PMID 27271593. https://doi.org/10.3390/ijms17060863
  81. Every-Palmer S, Nowitz M, Stanley J, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125-34. PMID 27077119. https://doi.org/10.1016/j.ebiom.2016.02.020
  82. Handley SA, Every-Palmer S, Ismail A, Flanagan RJ. Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992-2017. Br J Psychiatry. 2022;220(6):355-63. PMID 35164895. https://doi.org/10.1192/bjp.2022.24
  83. Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal slow gut reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31(8):699-709. PMID 28623627. https://doi.org/10.1007/s40263-017-0448-6
  84. Flanagan RJ, Handley SA, James C, et al. Clozapine-induced gastrointestinal hypomotility: UK pharmacovigilance reports, 2018-2022. BJPsych Open. 2025;11(3):e79. PMID 40162866. https://doi.org/10.1192/bjo.2025.29
  85. Every-Palmer S, Ellis PM, Nowitz M, et al. The Porirua protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study. CNS Drugs. 2017;31(1):75-85. PMID 27826741. https://doi.org/10.1007/s40263-016-0391-y
  86. Sundermann M, Every-Palmer S, Barclay M, Chin PKL. A clinical decision support alert to promote timely laxative use in in-patients prescribed clozapine. BJPsych Open. 2025;11(2):e51. PMID 40079118. https://doi.org/10.1192/bjo.2025.1
  87. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811-9. PMID 24777151. https://doi.org/10.1038/ajg.2014.82
  88. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77. PMID 31860457. https://doi.org/10.1016/S2215-0366(19)30416-X
  89. Fitzgerald I, Sahm LJ, Byrne A, et al. Predicting antipsychotic-induced weight gain in first episode psychosis: a field-wide systematic review and meta-analysis. Eur Psychiatry. 2023;66(1):e42. PMID 37278237. https://doi.org/10.1192/j.eurpsy.2023.2417
  90. Zhang JP, Lencz T, Zhang RX, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42(6):1418-37. PMID 27217270. 46 muestras, 6.700 pacientes. https://doi.org/10.1093/schbul/sbw058
  91. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018;361:k1951. PMID 29793997. https://doi.org/10.1136/bmj.k1951
  92. Stogios N, Agarwal SM, Maksyutynska K, et al. Pharmacological interventions for weight reduction in patients with schizophrenia treated with antipsychotics: a systematic review and network meta-analysis. JAMA Psychiatry. 2026. PMID 42418179. https://doi.org/10.1001/jamapsychiatry.2026.1814
  93. Hegde NC, Mishra A, Maiti R, et al. Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: a network meta-analysis. Gen Hosp Psychiatry. 2024;90:12-21. PMID 38878592. https://doi.org/10.1016/j.genhosppsych.2024.06.003
  94. Chen X, Wang DD, Li ZP. Time course and dose effect of metformin on weight in patients with different disease states. Expert Rev Clin Pharmacol. 2020;13(10):1169-77. PMID 32940086. Tiempo hasta la mitad del efecto maximo: 45,5 semanas. https://doi.org/10.1080/17512433.2020.1822164
  95. Calkin CV, Chengappa KNR, Cairns K, et al. Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (TRIO-BD): a randomized, quadruple-masked, placebo-controlled clinical trial. J Clin Psychiatry. 2022;83(2):21m14022. PMID 35120288. n = 45. La comparacion principal es conversores frente a no conversores, un subgrupo posterior a la aleatorizacion, no metformina frente a placebo. https://doi.org/10.4088/JCP.21m14022
  96. Kang M, Liu H, Hui J, et al. Metformin use on the risks of depression and anxiety in people with type 2 diabetes. Commun Med (Lond). 2025;5(1):302. PMID 40691522. UK Biobank, 11.379 pacientes con diabetes tipo 2. https://doi.org/10.1038/s43856-025-01006-2
  97. Dodd S, Sominsky L, Siskind D, et al. The role of metformin as a treatment for neuropsychiatric illness. Eur Neuropsychopharmacol. 2022;64:32-43. PMID 36191545. Revision narrativa. https://doi.org/10.1016/j.euroneuro.2022.09.002
  98. Battini V, Cirnigliaro G, Leuzzi R, et al. The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression. Front Psychiatry. 2023;14:1215807. PMID 37502816. https://doi.org/10.3389/fpsyt.2023.1215807
  99. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk (CAMP). Am J Psychiatry. 2011;168(9):947-56. PMID 21768610. https://doi.org/10.1176/appi.ajp.2011.10111609
  100. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339-47. PMID 26407790. https://doi.org/10.1002/wps.20252
  101. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015;132(2):144-57. PMID 25943829. https://doi.org/10.1111/acps.12439
  102. Fuller PM, Saper CB, Lu J. The pontine REM switch: past and present. J Physiol. 2007;584(Pt 3):735-41. PMID 17884926. https://doi.org/10.1113/jphysiol.2007.140160
  103. Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep. 2013;36(11):1579-85. PMID 24179289. https://doi.org/10.5665/sleep.3102
  104. Schramm PJ, Poland RE, Rao U. Bupropion response on sleep quality in patients with depression. Eur Neuropsychopharmacol. 2013;24(2):207-14. PMID 24239431. https://doi.org/10.1016/j.euroneuro.2013.09.007
  105. DelRosso LM, Mogavero MP, Fickensher A, et al. Effects of bupropion and SSRI antidepressants on leg movement activity and chin muscle tone during sleep in adolescents. J Clin Sleep Med. 2023;19(1):151-61. PMID 36073843. https://doi.org/10.5664/jcsm.10282
  106. Wu Z, Wu J, Xie C, Wang L, Li H, Zhang M. Risk factors for rapid eye-movement sleep-related behavioral disorders (RBDs): a systematic review and meta-analysis. Gen Hosp Psychiatry. 2022;79:118-27. PMID 36375340. https://doi.org/10.1016/j.genhosppsych.2022.10.009
  107. Alexandres CA, McCarter SJ, Tabatabai GM, et al. Phenoconversion in women and men with isolated REM sleep behavior disorder: a retrospective cohort study. Neurology. 2024;103(10):e209993. PMID 39454123. 372 pacientes de la Clinica Mayo, mediana de seguimiento 6,0 años. https://doi.org/10.1212/WNL.0000000000209993
  108. McCarter SJ, St Louis EK, Boeve BF. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep. 2012;12(2):182-92. PMID 22328094. https://doi.org/10.1007/s11910-012-0253-z
  109. Feige B, Voderholzer U, Riemann D, Dittmann R, Hohagen F, Berger M. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology. 2002;26(2):246-58. PMID 11790520. https://doi.org/10.1016/S0893-133X(01)00314-1
  110. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics. 2018;59(2):105-22. PMID 29275963. Revisión narrativa, no sistemática, con búsqueda estructurada en PubMed desde 2012; firmada por psiquiatras del Massachusetts General y cardiólogos electrofisiólogos de la Mayo. Es la fuente primaria de la nota del ACLP. https://doi.org/10.1016/j.psym.2017.10.009
  111. Funk MC, Beach SR, Bostwick JR, et al. QTc prolongation and psychotropic medications. Am J Psychiatry. 2020;177(3):273-4. PMID 32114782. Documento de recursos de la APA, con el aval del American College of Cardiology. No es una guía de práctica clínica, y sus autores lo dicen. https://doi.org/10.1176/appi.ajp.2019.1760501
  112. Funk MC, Lou J. The fundamentals of QTc: understanding risks and preventing problems. Psychiatric Times. 2021;38(11). Revisión narrativa de la misma primera autora del documento de la APA. https://www.psychiatrictimes.com/view/the-fundamentals-of-qtc
  113. Physicians «over-cautious about drug risks». ACLP News, marzo de 2018. Academy of Consultation-Liaison Psychiatry. Nota de prensa de sociedad científica sobre el trabajo de Beach y colaboradores. No es un artículo revisado por pares. https://clpsychiatry.org/aclp-news/y2018/m03/qt-prolongation-drug-risk/
  114. Zivin K, Pfeiffer PN, Bohnert ASB, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013;170(6):642-50. PMID 23640689. Cohorte retrospectiva de la Veterans Health Administration: 618.450 personas con citalopram y 365.898 con sertralina. https://doi.org/10.1176/appi.ajp.2013.12030408
  115. Rector TS, Adabag S, Cunningham F, Nelson D, Dieperink E. Outcomes of citalopram dosage risk mitigation in a veteran population. Am J Psychiatry. 2016;173(9):896-902. PMID 27166093. 35.848 veteranos que tomaban más de 40 mg cuando se emitió la alerta. Retrospectivo: la reducción de dosis no se asignó al azar. https://doi.org/10.1176/appi.ajp.2016.15111444
  116. Straley CM, Sochacki M, Reed E, Carr CN, Baugh TB. Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: a cross-sectional study. J Affect Disord. 2021;296:476-84. PMID 34649181. Transversal, 487 sujetos y 798 electrocardiogramas; 95 % varones, edad media 61 años. https://doi.org/10.1016/j.jad.2021.08.149
  117. AstraZeneca Pharmaceuticals LP. SEROQUEL (quetiapine) tablets, film coated. Ficha técnica de la FDA (prescribing information), revisada en enero de 2025. Sección 5.12, «QT Prolongation», en Warnings and Precautions. Ficha técnica del fabricante, aprobada por la FDA. No está indexada en PubMed; se consultó en DailyMed el 08-10-2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0584dda8-bc3c-48fe-1a90-79608f78e8a0
  118. Allergan, Inc. LEXAPRO (escitalopram) tablets and oral solution. Ficha técnica de la FDA (prescribing information), revisada en octubre de 2023. Sección 5, Warnings and Precautions, sin epígrafe sobre el QT; sección 6.1, «ECG Changes», con el estudio exhaustivo del QT en 113 voluntarios sanos; sección 7, tabla de interacciones, fila de la pimozida. Ficha técnica del fabricante, aprobada por la FDA. No está indexada en PubMed; se consultó en DailyMed el 08-10-2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13bb8267-1cab-43e5-acae-55a4d957630a
  119. Cheng SL, Hsu TW, Kao YC, et al. Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses. Crit Care. 2025;29(1):126. PMID 40114217. Doce ECA doble ciego contra placebo: siete de tratamiento (n = 1.767) y cinco de prevención (n = 2.509). Analiza los mismos datos con estadística frecuentista y bayesiana, y las dos lecturas no dicen lo mismo. https://doi.org/10.1186/s13054-025-05342-6
  120. Salluh JIF, Wang H, Schneider EB, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ. 2015;350:h2538. PMID 26041151. 42 estudios y 16.595 pacientes críticos. Mide la asociación entre el delirium y el desenlace, sin probar el efecto de ningún tratamiento. https://doi.org/10.1136/bmj.h2538
  121. Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol for the treatment of delirium in ICU patients (AID-ICU). N Engl J Med. 2022;387(26):2425-35. PMID 36286254. ECA multicéntrico con placebo, 1.000 pacientes. El desenlace principal no fue significativo; la diferencia de mortalidad a 90 días es un desenlace secundario. https://doi.org/10.1056/NEJMoa2211868
  122. Girard TD, Exline MC, Carson SS, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness (MIND-USA). N Engl J Med. 2018;379(26):2506-16. PMID 30346242. ECA doble ciego con placebo, 566 pacientes con delirium. https://doi.org/10.1056/NEJMoa1808217
  123. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU (PADIS). Crit Care Med. 2018;46(9):e825-73. PMID 30113379. Guía de práctica clínica de la Society of Critical Care Medicine: 37 recomendaciones, solo tres fuertes. https://doi.org/10.1097/CCM.0000000000003299
  124. Zhang WF, Tan YL, Zhang XY, Chan RCK, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615-21. PMID 20868638. Ensayo unico, sin replicar. https://doi.org/10.4088/JCP.09m05125yel
  125. Solmi M, Fornaro M, Caiolo S, et al. Efficacy and acceptability of pharmacological interventions for tardive dyskinesia: a systematic review and network meta-analysis. Mol Psychiatry. 2024;30(3):1207-22. PMID 39695322. https://doi.org/10.1038/s41380-024-02733-z
  126. Soares-Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1(1):CD000209. PMID 29341067. https://doi.org/10.1002/14651858.CD000209.pub3
  127. Lerner V, Bergman J, Statsenko N, Miodownik C. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65(11):1550-4. PMID 15554771. https://doi.org/10.4088/jcp.v65n1118

Siguiente paso

Quién los produceTodos los fármacosEn qué cuadroDiagnósticos